Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Page 1
TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
J Pathol. 2024 Jun;263(2):139-149. doi: 10.1002/path.6266. Epub 2024 Feb 21.
J Pathol. 2024.
PMID: 38380548
POLQ identifies a better response subset to immunotherapy in muscle-invasive bladder cancer with high PD-L1.
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Chang Y, Wang Y, Zhu Y, Xu L, Xu J, Wang Z, Liu H, Zhang W.
Liu G, et al.
Cancer Med. 2024 Feb;13(4):e6962. doi: 10.1002/cam4.6962.
Cancer Med. 2024.
PMID: 38457207
Free PMC article.
Item in Clipboard
Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
Xu Z, Jiang W, Liu L, Qiu Y, Wang J, Dai S, Guo J, Xu J.
Xu Z, et al.
Cancer Immunol Immunother. 2024 Apr 12;73(5):95. doi: 10.1007/s00262-024-03681-x.
Cancer Immunol Immunother. 2024.
PMID: 38607586
Free PMC article.
Item in Clipboard
Cite
Cite